Progenics Pharmaceuticals (PGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2020 | 12-2019 | 09-2019 | 06-2019 | 03-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -16,801 | -68,552 | -57,277 | -38,435 | -18,735 |
| Depreciation Amortization | 742 | 2,366 | 1,767 | 1,166 | 557 |
| Income taxes - deferred | N/A | 6 | N/A | N/A | N/A |
| Accounts receivable | 9,786 | -12,176 | -2,374 | -6,764 | -1,136 |
| Other Working Capital | 7,813 | -14,108 | -5,181 | -5,468 | -2,400 |
| Other Operating Activity | -9,147 | 17,766 | 7,194 | 10,801 | 3,195 |
| Operating Cash Flow | $-7,607 | $-74,698 | $-55,871 | $-38,700 | $-18,519 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -3,553 | -7,231 | -4,465 | -1,827 | -491 |
| Net Acquisitions | N/A | -8,000 | -8,000 | -8,000 | -8,000 |
| Other Investing Activity | 0 | -277 | -277 | -277 | 0 |
| Investing Cash Flow | $-3,553 | $-15,508 | $-12,742 | $-10,104 | $-8,491 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -1,682 | -5,843 | -3,880 | -2,590 | -1,037 |
| Common Stock Issued | 162 | 1,942 | 1,313 | 267 | N/A |
| Financing Cash Flow | $-1,520 | $-3,901 | $-2,567 | $-2,323 | $-1,037 |
| Exchange Rate Effect | -201 | -48 | -220 | 2 | -46 |
| Beginning Cash Position | 45,065 | 139,220 | 139,220 | 139,220 | 139,220 |
| End Cash Position | 32,184 | 45,065 | 67,820 | 88,095 | 111,127 |
| Net Cash Flow | $-12,881 | $-94,155 | $-71,400 | $-51,125 | $-28,093 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,607 | -74,698 | -55,871 | -38,700 | -18,519 |
| Capital Expenditure | -3,553 | -7,231 | -4,465 | -1,827 | -491 |
| Free Cash Flow | -11,160 | -81,929 | -60,336 | -40,527 | -19,010 |